Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
MONTREAL, March 7, 2017 – Milestone Pharmaceuticals USA, Inc., a clinical stage cardiovascular company, today announced the appointment of Joseph G. Oliveto as President and Chief Executive Officer, effective immediately. His appointment follows a recent, successful outcome from the company’s Phase 2 study of lead candidate etripamil for the acute treatment of paroxysmal supra-ventricular tachycardia (PSVT), a potentially debilitating cardiac arrhythmia. Mr. Oliveto brings more than 25 years of pharmaceutical and biotech experience across the areas of drug development, commercialization, manufacturing and business development to Milestone. Philippe Douville, Ph.D., who founded the company and served as CEO, will now assume the newly created position of Chief Scientific Officer.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.